Armed Antibody Company Launches New Trial
A little over two years ago, we began following Seattle Genetics. The company owns a technology improving antibody-based therapies. By adding a toxin payload to a cancer-homing antibody with a special chemical linker, Seattle Genetics one-ups the current crop of chemotherapy and antibody therapies in both targeting and lethality. It is a new generation of cancer-fighting technology. Seattle Genetics is the first company to market a cancer therapy using this type of technique, but the company isn't alone. One other, ImmunoGen, is in late stages with its own version of this platform.
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Technology Profits Confidential
With new technologies in mobile computing, biotechnology and 3-D printing, it’s nearly impossible to keep up with the throngs of new innovation and still be able to forecast which companies are set to profit. Technology Profits Confidential is your one-stop shop for the companies of tomorrow’s technology… and how you can profit from them.